The US Food and Drug Administration’s biologics center is considering ways to streamline the development and regulatory review of genome editing technology targeted at different mutations of the same gene.
The Center for Biologics Evaluation and Research “is working on developing a guidance on genome editing technology under the platform framework,” Julie Tierney, deputy center director for strategy, policy and...
Key Takeaways
-
CBER is developing guidance on how genome editing technology can leverage the platform framework.
-
The FDA could grant approval for treating all mutations in...